Delcath Systems (NSDQ:DCTH) said today that doctors in Europe performed the 500th percutaneous hepatic perfusion therapy treatment using Delcath’s Chemosat delivery system.
The drug-device combo has been available in certain European markets since 2012.
Get the full story at our sister site, Drug Delivery Business News.
The post Delcath touts 500th commercial Chemosat treatment in Europe appeared first on MassDevice.